Tacrolimus dosage requirements in living donor liver transplant recipients with small-for-size grafts.
OBJECTIVE
To investigate the tacrolimus dosage requirements and blood concentrations in adult-to-adult right lobe living donor liver transplantation (AALDLT) recipients with small-for-size (SFS) grafts.


METHODS
During January 2007 and October 2008, a total of 54 cases of AALDLT with an observation period of 6 mo were enrolled in this study. The 54 patients were divided into two groups according to graft-recipient body weight ratio (GRBW): SFS grafts group (Group S, GRBW < 0.8%, n = 8) and non-SFS grafts group (Group N, GRBW > or = 0.8%, n = 46). Tacrolimus 12-hour blood levels and doses were recorded during weeks 1, 2, 3 and 4 and months 2, 3, 4, 5 and 6 in group S and group N. Meanwhile, acute rejection rates, liver and renal function test results, and the number of potentially interacting medications were determined at each interval in the two groups. A comparison of tacrolimus dosage requirements and blood levels were made weekly in the first month post-surgery, and monthly from months 2 to 6.


RESULTS
There were no differences in the demographic characteristics, acute rejection rates, liver and renal function test results, or the number of potentially interacting medications administered between the two groups. The tacrolimus dosage requirements in group S were significantly lower than group N at 2 wk (2.8 +/- 0.4 mg/d vs 3.6 +/- 0.7 mg/d, P = 0.006), 3 wk (2.9 +/- 0.7 mg/d vs 3.9 +/- 0.8 mg/d, P = 0.008), 4 wk (2.9 +/- 0.8 mg/d vs 3.9 +/- 1.0 mg/d, P = 0.023) and 2 mo (2.8 +/- 0.7 mg/d vs 3.8 +/- 1.1 mg/d, P = 0.033). Tacrolimus 12-h trough concentrations were similar between the two groups at all times except for 2 wk post-transplantation, when the concentrations were significantly greater in group S recipients than in group N recipients (11.3 +/- 4.8 ng/mL vs 7.0 +/- 3.8 ng/mL, P = 0.026).


CONCLUSIONS
SFS grafts recipients have significantly decreased tacrolimus dosage requirements compared with non-SFS grafts recipients in AALDLT during the first 2 mo post-surgery.
Liu
Fei
F
Department of Liver and Vascular Surgery, Center of Liver Transplantation, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China.
Li
Ya
Y
Lan
Xiang
X
Wei
Yong-Gang
YG
Li
Bo
B
Yan
Lv-Nan
LN
Wen
Tian-Fu
TF
Zhao
Ji-Chun
JC
Xu
Ming-Qing
MQ
Wang
Wen-Tao
WT
Yang
Jia-Yin
JY
D000328:Adult; D000368:Aged; D001835:Body Weight; D005260:Female; D006085:Graft Survival / Q000187:drug effects*; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D016031:Liver Transplantation; D019520:Living Donors; D008297:Male; D008875:Middle Aged; D009929:Organ Size; D016559:Tacrolimus / Q000494:pharmacology*; D016896:Treatment Outcome; D055815:Young Adult
D007166:Immunosuppressive Agents; D016559:Tacrolimus
Clin Pharmacokinet. 1995 Dec;29(6):404-30
8787947
Hepatology. 2000 Jul;32(1):49-55
10869288
Transplantation. 2000 Dec 27;70(12):1697-703
11152099
Clin Transplant. 2003 Oct;17(5):412-6
14703922
Clin Transplant. 2002 Apr;16(2):102-6
11966779
Mol Pharmacol. 1993 Oct;44(4):707-15
8232220
Clin Transplant. 2004 Apr;18(2):124-9
15016124
Biol Pharm Bull. 2005 Sep;28(9):1805-8
16141567
Drug Metab Dispos. 2009 Apr;37(4):821-6
19139162
Pharmacotherapy. 2006 Aug;26(8):1069-77
16863483
Transplantation. 2000 Apr 15;69(7):1375-9
10798757
Transplant Proc. 1995 Feb;27(1):1108-10
7533356
Eur J Clin Pharmacol. 2001 Sep;57(6-7):479-84
11699612
Pharm Res. 1998 Oct;15(10):1609-13
9794505
Transplant Proc. 1991 Feb;23(1 Pt 2):1397-402
1703340
Surgery. 1990 Apr;107(4):417-27
2181716
Transplantation. 2002 Jan 15;73(1):159-60
11793001
Liver Transpl. 2004 Mar;10(3):374-8
15004764
Clin Transplant. 2006 Jul-Aug;20(4):443-9
16842519
Transplantation. 2003 Jul 15;76(1):5-10
12865779
J Pharmacol Exp Ther. 1998 Feb;284(2):760-7
9454825
Hepatology. 1989 Mar;9(3):393-7
2920995
Liver Transpl. 2002 Mar;8(3):219-23
11910566
Hepatogastroenterology. 2007 Oct-Nov;54(79):2078-83
18251163
Transplantation. 2008 Feb 27;85(4):554-60
18347534
Drug Metab Dispos. 1988 Jul-Aug;16(4):582-9
2903027
Transpl Int. 2002 Jul;15(7):355-60
12122512
Transpl Int. 2003 Nov;16(11):814-9
12879228